Previous in vivo studies in lung cancer showed that decreased EGFR level might be involved in the antiproliferative effect of GHRH antagonists [49,50], but it hasn't been reported in ovarian cancer cell lines by JMR-132 treatment. The gene discussed is EGFR; the disease is ovarian carcinoma.